Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors

Current Oncology

Volumn 21, Issue 6, 2014, Pages 329-336

  Hirsh, V ^a   Blais, N ^b   Burkes, R ^c   Verma, S ^c   Croitoru, K ^d  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Adverse events; Diarrhea management; Epidermal growth factor receptor; Non small cell lung cancer; Tyrosine kinase inhibitors

Indexed keywords

AFATINIB; ATROPINE; CODEINE; DACOMITINIB; DIPHENOXYLATE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; LOPERAMIDE; PROBIOTIC AGENT;

ARTICLE; DEHYDRATION; DIARRHEA; DIET; DISEASE SEVERITY; DRUG USE; EDUCATION; ELECTROLYTE DISTURBANCE; GASTROINTESTINAL MUCOSA; HUMAN; INCIDENCE; LACTOBACILLUS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; SUPPLEMENTATION;

EID: 84916216758     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.21.2241     Document Type: Article

References (73)

1. American Cancer Society. Home > Learn About Cancer > Lung Cancer-Non-Small Cell > Detailed Guide > What is non-small cell lung cancer? [Web page]. Atlanta, GA: American Cancer Society; 2014. [Available at: http://www.cancer. org/Cancer/LungCancer-Non-SmallCell/DetailedGuide/nonsmall- cell-lung-cancer-what-is-non-small-cell-lung-cancer; cited May 19, 2014]
2. American Cancer Society. Cancer Facts and Figures 2013. Atlanta, GA: American Cancer Society; 2013
3. Ladanyi M, Pao W. Lung adenocarcinoma: guiding egfrtargeted therapy and beyond. Mod Pathol 2008;21(suppl 2):S16-S22
4. Carpenter RL, Lo HW. Dacomitinib, an emerging hertargeted therapy for non-small cell lung cancer. J Thorac Dis 2012;4:639-42
5. Jang TW, Oak CH, Chang HK, Suo SJ, Jung MH. EGFR and KRAS mutations in patients with adenocarcinoma of the lung. Korean J Intern Med 2009;24:48-54
6. American Cancer Society. Home > Learn About Cancer > Lung Cancer-Non-Small Cell > Detailed Guide > Targeted therapies for non-small cell lung cancer [Web page]. Atlanta, GA; 2014. [Available at: http://www.cancer.org/cancer/ lungcancer-non-smallcell/detailedguide/non-small-cell-lungcancer- treating-targeted-therapies; cited May 6, 2014]
7. Shaw A, Rudin C, Spigel A, Goss G. Molecular Markers in Advanced NSCLC (Part 2): Results of Broad Testing in Advanced NSCLC [slide presentation]. Boston, MA; 2012. [Available online at: http://cancergrace.org/lung/files/2012/04/ Molecular-Markers-SM-Pt-2-Shaw-on-Markers-by-Clin- Factors-Figs.pdf; cited May 1, 2012]
8. Hirsh V. Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-smallcell lung cancer. Curr Oncol 2011;18:126-38
9. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase ii trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the ideal 1 trial) [corrected]. J Clin Oncol 2003;21:2237-46. [Erratum in: J Clin Oncol 2004;22:4863]
10. Rosell R, Carcereny E, Gervais R, et al. on behalf of the Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapyas first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (eurtac): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46
11. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (optimal, ctong-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42
12. Mitsudomi T, Morita S, Yatabe Y, et al. on behalf of the West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (wjtog3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8
13. Landi L, Cappuzzo F. Irreversible egfr-tkis: dreaming perfection. Transl Lung Cancer Res 2013;2:40-9
14. Stoehlmacher Williams J, Ehninger G, Zimmermann DR, Merkelbach Bruse S, Schildhaus HU, Buettner R. Targeting tki-resistance in nsclc: importance of rebiopsy and molecular diagnostics—a case study. Cancer Treat Comm 2013;1:1-5
15. Meador CB, Jin H, de Stanchina E, et al. Acquired resistance to afatinib plus cetuximab in EGFR-mutant lung adenocarcinoma may be mediated by egfr overexpression and overcome by the mutant-specific egfr inhibitor, AZD9291 [abstract B10]. Clin Cancer Res 2014;20(suppl 2):.
16. Belani CP. The role of irreversible egfr inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible egfr inhibitors. Cancer Invest 2010;28:413-23
17. Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible egfr/her2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27:4702-11
18. Hirsh V. Afatinib (BIBW 2992) development in non-small-cell lung cancer. Future Oncol 2011;7:817-25
19. AstraZeneca Canada. Iressa: Gefitinib Tablets [product monograph]. Mississauga, ON: AstraZeneca Canada; 2012
20. Hoffmann-La Roche. Tarceva: Erlotinib Hydrochloride Tablets [product monograph]. Mississauga, ON: Hoffmann-La Roche; 2013
21. Yang JC, Reguart N, Barinoff J, et al. Diarrhea associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther 2013;13:729-36
22. Harandi A, Zaidi AS, Stocker AM, Laber DA. Clinical efficacy and toxicity of anti-egfr therapy in common cancers. J Oncol 2009;2009:567486
23. Loriot Y, Perlemuter G, Malka D, et al. Drug insight: gastrointestinal and hepatic adverse effects of moleculartargeted agents in cancer therapy. Nature Clin Pract Oncol 2008;5:268-78
24. Uribe JM, Gelbmann CM, Traynor Kaplan AE, Barrett KE. Epidermal growth factor inhibits Ca2+-dependent Cl- transport in T84 human colonic epithelial cells. Am J Physiol 1996;271:C914-C22
25. Bowen JM. Mechanisms of tki-induced diarrhea in cancer patients. Curr Opin Support Palliat Care 2013;7:162-7
26. Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (stepp), a phase ii, openlabel, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:1351-7
27. United States, Department of Health and Human Services, National Institutes of Health, National Cancer Institute (nci). Common Terminology Criteria for Adverse Events. Ver. 4.03. Bethesda, MD; 2010. [Available online at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_ QuickReference:5x7.pdf; cited April 29, 2012]
28. Maroun JA, Anthony LB, Blais N, et al. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Curr Oncol 2007;14:13-20
29. BC Cancer Agency (bcca). BCCA Guidelines for Management of Chemotherapy-Induced Diarrhea. Vancouver, BC: bcca; 2004. [Available online at: http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/SupportiveCare/Chemo therapy-Induced+Diarrhea.htm; cited January 13, 2014]
30. Herbst RS, Prager D, Hermann R, et al. on behalf of the tribute Investigator Group. tribute: a phase iii trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-9
31. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. on behalf of the nci Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32
32. Cho BC, Im CK, Park MS, et al. Phase ii study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 2007;25:2528-33
33. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase iii study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-52
34. Jackman DM, Yeap BY, Lindeman NI, et al. Phase ii clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007;25:760-6
35. Felip E, Rojo F, Reck M, et al. A phase ii pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res 2008;14:3867-74
36. Lilenbaum R, Axelrod R, Thomas S, et al. Randomized phase ii trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol 2008;26:863-9
37. Mok TS, Wu YL, Yu CJ, et al. Randomized, placebo-controlled, phase ii study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2009;27:5080-7
38. Bennouna J, Besse B, Leighl NB, et al. Everolimus plus erlotinib versus erlotinib alone in previously treated patients with advanced non-small cell lung cancer (nsclc) [abstract 419P]. Ann Oncol 2010;21(suppl 8):140
39. Groen H, Socinski M, Grossi F, et al. Randomized phase ii study of sunitinib (su) plus erlotinib (e) vs. placebo (p) plus e for the treatment of metastatic non-small cell lung cancer (nsclc) [abstract 417P]. Ann Oncol 2010;21(suppl 8):139
40. Kelly K, Azzoli CG, Zatloukal P, et al. Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage iiib/iv non-small-cell lung cancer (nsclc) after failure of prior platinum-based therapy. J Thorac Oncol 2012;7:1041-8
41. Scagliotti GV, Krzakowski MJ, Szczesna A, et al. Sunitinib (su) in combination with erlotinib (e) for the treatment of advanced/ metastatic nonsmall cell lung cancer (nsclc): a phase iii study [abstract LBA6]. Ann Oncol 2010;21(suppl 8):3
42. Zhao HY, Gongyan C, Feng J, et al. A phase ii study of erlotinib plus capecitabine (xel) as first line treatment for Asian elderly patients (pts) with advanced adenocarcinoma of lung (ml 22206 study) [abstract 420P]. Ann Oncol 2010;21(suppl 8):140
43. Natale RB, Thongprasert S, Greco FA, et al. Phase iii trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011;29:1059-66
44. Ciuleanu T, Stelmakh L, Cicenas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (titan): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012;13:300-8
45. Garassino MC, Martelli O, Broggini M, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (tailor): a randomised controlled trial. Lancet Oncol 2013;14:981-8
46. Lee SM, Khan I, Upadhyay S, et al. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (topical): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2012;13:1161-70
47. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58
48. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase iii trial—intact 1. J Clin Oncol 2004;22:777-84
49. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase ii trial—intact 2. J Clin Oncol 2004;22:785-94
50. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37
51. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (interest): a randomised phase iii trial. Lancet 2008;372:1809-18
52. Goss G, Ferry D, Wierzbicki R, et al. Randomized phase ii study of gefitinib compared with placebo in chemotherapynaive patients with advanced non-small-cell lung cancer and poor performance status. J Clin Oncol 2009;27:2253-60
53. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57
54. Gaafar RM, Surmont V, Scagliotti G, et al. A double-blind, randomized, placebo-controlled phase iii Intergroup study of gefitinib (g) in patients (pts) with advanced nsclc, nonprogressing after first-line platinum-based chemotherapy (eortc 08021-ilcp 01/03) [abstract 7518]. J Clin Oncol 2010;28:. [Available online at: http://meeting.ascopubs.org/cgi/content/ abstract/28/15_suppl/7518; cited October 20, 2014]
55. Shi Y, Zhang L, Liu X, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (icogen): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol 2013;14:953-61
56. Miller VA, Hirsh V, Cadranel J, et al. Phase iib/iii double-blind randomized trial of afatinib (BIBW 2992, an irreversible inhibitor of egfr/her1 and her2) + best supportive care (bsc) versus placebo + bsc in patients with nsclc failing 1-2 lines of chemotherapy and erlotinib or gefitinib (lux-Lung 1) [abstract LBA1]. Ann Oncol 2010;21(suppl 8):1
57. Yang C, Shih J, Su W, et al. A phase ii study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (lux-Lung 2) [abstract 367D]. Ann Oncol 2010;21(suppl 8):123
58. lux-Lung 5: afatinib (BIBW 2992) plus weekly paclitaxel versus investigator’s choice of single agent chemotherapy following afatinib monotherapy in non-small cell lung cancer patients failing erlotinib or gefitinib [Web page]. Bethesda, MD: ClinicalTrials.gov; 2012. [Available at: http://clinicaltrials.gov/ct2/show/NCT01085136; cited April 25, 2012]
59. Wu YL, Zhou C, Hu CP, et al. lux-Lung 6: a randomized, open-label, phase iii study of afatinib (a) versus gemcitabine/ cisplatin (gc) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung [abstract 8016]. J Clin Oncol 2013;31:. [Available online at: http://meetinglibrary.asco.org/ content/112318-132; cited October 20, 2012]
60. Yang JCH, Schuler MH, Yamamoto N, et al. lux-Lung 3: a randomized, open-label, phase iii study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFRactivating mutations [abstract LBA7500]. J Clin Oncol 2012;30:. [Available online at: http://meetinglibrary.asco.org/ content/91942-114; cited October 20, 2012]
61. Janne PA, Reckamp K, Koczywas M, et al. Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced nsclc after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (e): a two-arm, phase ii trial [abstract 8063]. J Clin Oncol 2009;27:. [Available online at: http://meetinglibrary.asco.org/content/32872-65; cited October 20, 2012]
62. Mok T, Spigel DR, Park K, et al. E fficacy a nd s afety o f PF299804 as first-line treatment (tx) of patients (pts) with advanced (adv) nsclc selected for activating mutation (mu) of epidermal growth factor receptor (egfr) [abstract LBA18]. Ann Oncol 2010;21(suppl 8):8
63. Ramalingam SS, Blackhall F, Krzakowski M, et al. Randomized phase ii study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2012;30:3337-44
64. Takahashi T, Boku N, Murakami H, et al. First report of the safety, pharmacokinetics, and preliminary activity of PF299804 in Japanese patients (pts) with advanced solid tumors [abstract 533P]. Ann Oncol 2010;21(suppl 8):174-5
65. Yang JCH, Sequist LV, O’Byrne KJ, et al. Epidermal growth factor receptor (egfr)-mediated adverse events in patients with EGFR mutation positive (EGFR M+) non-small cell lung cancer treated with afatinib [abstract 895]. Eur J Cancer 2013;49(suppl 2):.
66. Katakami N, Atagi S, Goto K, et al. lux-Lung 4: a phase ii trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 2013;31:3335-41
67. Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (lux-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:213-22
68. Sequist LV, Yang JCH, Yamamoto N, et al. Comparative safety profile of afatinib in Asian and non-Asian patients with EGFR mutation-positive (EGFR M+) non-small cell lung cancer (nsclc) [abstract P3.11-023]. J Thorac Oncol 2013;8(suppl 2):S1197
69. Thomas SK, Fossella FV, Liu D, et al. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer 2006;7:326-31
70. Cohen EE, Halpern AB, Kasza K, Kocherginsky M, Williams R, Vokes EE. Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral Oncol 2009;45:e155-e60
71. Saltz LB. Understanding and managing chemotherapy-induced diarrhea. J Support Oncol 2003;1:35-46
72. Salari P, Nikfar S, Abdollahi M. A meta-analysis and systematic review on the effect of probiotics in acute diarrhea. Inflamm Allergy Drug Targets 2012;11:3-14
73. Österlund P, Ruotsalainen T, Korpela R, et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer 2007;97:1028-34.